Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: A preliminary study

Pediatric Pulmonology

Volumn 31, Issue 5, 2001, Pages 367-376

  Master, Vahid ^a   Roberts, G W ^a,b   Coulthard, K P ^a,b   Baghurst, P A ^a   Martin, A ^a   Roberts, M E ^b   Onishko, C R ^a   Martin, A J ^a   Linke, R J ^b   Holmes, M ^c   Jarvinen, A ^a   Kennedy, D ^a   Colebatch, K A ^c   Hansman, D ^a   Parsons, D W ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cystic fibrosis; Once daily tobramycin monotherapy; Pseudomonas aeruginosa; Pulmonary exacerbations

Indexed keywords

CEFTAZIDIME; CREATININE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; AUDIOLOGY; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; CHILD; CYSTIC FIBROSIS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 0035022380     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.1060     Document Type: Article

References (43)

1. Microbiology of lung infections in cystic fibrosis patients
2. Infection and inflammation of the lung in cystic fibrosis
3. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
4. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: Current status of the host bacterium interaction
5. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis
6. Antimicrobial chemotherapy in cystic fibrosis patients
7. Acute pulmonary exacerbations in cystic fibrosis: A double-blind trial of tobramycin and placebo therapy
8. Treatment of infections in patients with cystic fibrosis
9. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
10. Management of pulmonary disease in patients with cystic fibrosis
11. Combination therapy: A way to limit emergence of resistance?
12. Combination antimicrobial therapy for bacterial infections
13. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis
14. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis
15. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo
16. Once daily aminoglycoside therapy
17. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis
18. Once versus thrice daily gentamicin in patients with serious infections
19. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
20. A suggested approach to once daily aminoglycoside dosing
21. Kinetic model for gentamicin dosing with the use of individual patient parameters
22. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis
23. Evaluation of scoring system of the chest radiograph in cystic fibrosis: A collaborative study
24. A new prognostic score and clinical evaluation system for cystic fibrosis
25. Analysis of longitudinal data: Issues in the design of controlled clinical trials in cystic fibrosis research
26. 1
27. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
28. Single or multiple daily doses of aminoglycosides: A meta-analysis
29. Alternative dosing strategy for aminoglycosides: Impact on efficacy, nephrotoxicity and ototoxicity
30. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats
31. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis
32. Variability of tobramycin pharmacokinetics in cystic fibrosis
33. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing
34. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
35. The post antibiotic effect: A review of in vitro and in vivo data
36. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model
37. Aminoglycoside toxicity and relation to dose regimen
38. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
39. Comparison of a β-lactam alone vs. β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis
40. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
41. Variability of pulmonary function tests in cystic fibrosis
42. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis